Repligen Corporation (NASDAQ:RGEN) Stock Has Average Target Price of $175.71

Shares of Repligen Corporation (NASDAQ:RGEN) have received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $175.71.

A number of brokerages have commented on RGEN. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Citigroup raised shares of Repligen to a “buy” rating in a research note on Tuesday, July 7th. Wells Fargo & Company lifted their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Zacks Research downgraded shares of Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Finally, Evercore reissued an “outperform” rating and set a $160.00 target price on shares of Repligen in a research report on Monday, July 6th.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $180.17 on Friday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $100.99 and a twelve month high of $198.87. The stock’s 50 day moving average is $177.37 and its 200-day moving average is $144.96. The firm has a market capitalization of $10.17 billion, a price-to-earnings ratio of 246.81, a PEG ratio of 3.23 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%. The company had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. During the same period last year, the business earned $0.26 EPS. Repligen’s quarterly revenue was up 11.9% compared to the same quarter last year. Sell-side analysts forecast that Repligen will post 2.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

Hedge funds have recently added to or reduced their stakes in the stock. Evergreen Capital Management LLC purchased a new stake in shares of Repligen in the third quarter worth approximately $217,000. Gibbs Wealth Management lifted its holdings in shares of Repligen by 7.7% in the third quarter. Gibbs Wealth Management now owns 12,866 shares of the biotechnology company’s stock valued at $2,473,000 after purchasing an additional 917 shares in the last quarter. Yousif Capital Management LLC lifted its holdings in shares of Repligen by 1.3% in the third quarter. Yousif Capital Management LLC now owns 12,604 shares of the biotechnology company’s stock valued at $2,423,000 after purchasing an additional 160 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Repligen by 3.5% in the third quarter. Crossmark Global Holdings Inc. now owns 4,525 shares of the biotechnology company’s stock valued at $870,000 after purchasing an additional 152 shares in the last quarter. Finally, Diversify Advisory Services LLC lifted its holdings in shares of Repligen by 7.7% in the third quarter. Diversify Advisory Services LLC now owns 20,028 shares of the biotechnology company’s stock valued at $3,689,000 after purchasing an additional 1,434 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.